Contemporary clinical trials · 2026
Land- and water-based supervised exercise intervention for women with fibromyalgia: a CERT-based protocol from the al-Ándalus randomized controlled trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Álvarez-Gallardo Inmaculada C, Gavilán-Carrera Blanca, Carbonell-Baeza Ana, Segura-Jiménez Víctor, Camiletti-Moirón Daniel, Borges-Cosic Milkana, Aparicio Virginia, Delgado-Fernández Manuel
Аннотация
BACKGROUND: Exercise is a core non-pharmacological treatment for fibromyalgia and is consistently recommended in clinical guidelines. However, exercise interventions are often inadequately reported, limiting reproducibility, implementation in clinical practice, and comparison across studies.
AIM: This article aims to provide a comprehensive description of the rationale, design, and delivery of the land- and water-based exercise interventions implemented in the al-Ándalus Randomized Controlled Trial (RCT), following the Consensus on Exercise Reporting Template (CERT).
METHODS: Women aged 35-65 years diagnosed with fibromyalgia (n = 180) were recruited in Southern Spain (Andalucía) and allocated to one of three groups: usual care (control), land-based supervised exercise, or water-based supervised exercise (n = 60 per group). Participants in the intervention groups completed a 24-week supervised multicomponent exercise program comprising aerobic, strength, and flexibility training delivered three times per week on non-consecutive days (45-60 min/session). The intervention rationale, progression criteria, supervision procedures, adherence strategies, and exercise components are reported according to the 16-item CERT checklist.
DISCUSSION: This report provides a detailed and standardised description of a supervised multicomponent exercise intervention for women with fibromyalgia delivered in both land- and water-based settings. By facilitating transparency, reproducibility, and implementation, the protocol may serve as a practical resource for clinicians and exercise professionals and as a methodological reference for researchers seeking to improve the reporting quality of exercise interventions in fibromyalgia and other chronic musculoskeletal conditions.
TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT01490281.
AIM: This article aims to provide a comprehensive description of the rationale, design, and delivery of the land- and water-based exercise interventions implemented in the al-Ándalus Randomized Controlled Trial (RCT), following the Consensus on Exercise Reporting Template (CERT).
METHODS: Women aged 35-65 years diagnosed with fibromyalgia (n = 180) were recruited in Southern Spain (Andalucía) and allocated to one of three groups: usual care (control), land-based supervised exercise, or water-based supervised exercise (n = 60 per group). Participants in the intervention groups completed a 24-week supervised multicomponent exercise program comprising aerobic, strength, and flexibility training delivered three times per week on non-consecutive days (45-60 min/session). The intervention rationale, progression criteria, supervision procedures, adherence strategies, and exercise components are reported according to the 16-item CERT checklist.
DISCUSSION: This report provides a detailed and standardised description of a supervised multicomponent exercise intervention for women with fibromyalgia delivered in both land- and water-based settings. By facilitating transparency, reproducibility, and implementation, the protocol may serve as a practical resource for clinicians and exercise professionals and as a methodological reference for researchers seeking to improve the reporting quality of exercise interventions in fibromyalgia and other chronic musculoskeletal conditions.
TRIAL REGISTRATION: ClinicalTrials.gov ID: NCT01490281.